Loading...
Loading...
Clinical decision support tool. Does not replace professional veterinary judgment. Always verify recommendations with current references.
Thinking about this breed for your home? Read the owner suitability guide
Prevalence: Unknown
Sighthound anesthetic sensitivity. Low body fat and reduced CYP2B11 activity. Reduce induction dose by 25-50%.
Prevalence: Variable by breed line
Simparica Trio contains moxidectin (0.024-0.048 mg/kg), a macrocyclic lactone and P-glycoprotein substrate. In MDR1-mutant dogs, moxidectin accumulates in CNS causing dose-dependent neurotoxicity. FDA label warns against use in MDR1-affected breeds.
Also avoid: Simparica Trio, moxidectin, ivermectin
Sarolaner alone (Simparica, not Trio) is safe in MDR1 breeds
Also avoid: ivermectin, milbemycin oxime, moxidectin, loperamide
Test for MDR1 mutation before prescribing macrocyclic lactones in herding breeds (WSU MDR1 test available)
Also avoid: Heartgard, ivermectin, moxidectin
Use Interceptor (milbemycin) with caution — also MDR1-substrate at higher doses; preventive doses generally safe but verify
Low body fat → prolonged recovery from lipid-soluble agents (thiopental, propofol). Reduce induction doses 25-50%. Use lean-body-mass dosing. CYP2B11 deficiency in Greyhounds = slow barbiturate/propofol metabolism. Prefer alfaxalone for induction. Extended post-anesthetic monitoring required.